



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 112408-122

Applicant: Carr, et al.

Filed: March 3, 2000

Serial No.: 09/518,813

Entitled: Methods for Protein Screening

Examiner: P. Ponnaluri

Art Unit: 1627

TECH CENTER 1600/2900

APR 05 2002

RECEIVED

1627
13/Election
efm
3-20-02

CERTIFICATION UNDER 37 CFR § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, DC 20231.

3/30/02
Date of Signature and
of Mail Deposit

Sharon R. Matthews
Sharon R. Matthews

Set
4-8-02

Commissioner of Patents
Washington, D.C. 20231

RESPONSE TO A RESTRICTION REQUIREMENT

Dear Sir:

Claims 1-11, 14-15, 24-42, and 57 are pending in this application, and are subject to a Restriction Requirement dated November 20, 2001.

Applicant requests a four-month extension of time up to and including March 20, 2002 to respond to the Restriction Requirement mailed November 20, 2001. Please charge our Deposit Account No. 08-0219 the required fee pursuant to 37 C.F.R. 1.17(a)(4).

Applicant believes no additional fees are due with this filing. However, please charge any underpayments or credit any overpayments to our Deposit Account No. 08-0219.

Applicant elects the claims of Group I (claims 1-11, 14-15, and 24-42), drawn to a method of screening proteins or polypeptides, for examination at this time.


In response to the election of species requirement, Applicant elects the following species for examination at this time: binding to protein as the property for which the polypeptides are screened; (poly) peptide as the molecule derived from the target cell; HIV tat as the liposome content, streptavidin as the label molecule; immobilized (versus not immobilized), and glass slide (versus multi-well plate).

Applicant respectfully submits that it is not possible to elect a specific protein or polypeptide synthesized from the gene library because the invention is directed to methods of screening which identifies previously unknown proteins, ligands, binding partners, and other molecules. Therefore, it is not reasonable to identify a single protein prior to screening.

If the restriction requirement is maintained, Applicant understands that upon a finding of a generic claim, Applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all of the limitations of an allowed generic claim as provided by 37 C.F.R § 1.141.

If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,



Hollie L. Baker
Attorney for Applicant
Reg. No. 31,321

Date: March 20, 2002
HALE AND DORR LLP
60 State Street
Boston, MA 02109
Tel: (617) 526-6110
Fax: (617) 526-5000